What Canadians should know about RSV and how to prevent it this winter
RSV is a common virus that affects the lungs and breathing passages, and here are some steps you can take to protect yourself ...
Is it game over for the GSK share price?
Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...
dermatologyadvisor3d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
STAT3d
With little fanfare, Biden administration stacked vaccine advisory committee with new members
With little fanfare, the Biden administration stacked a critical committee that helps set U.S. vaccination policy with new ...
BioSpace4d
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
GlobalData on MSN4d
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
RSV vaccines are available for vulnerable adults and the ill. They just can’t afford them.
Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...
The American Journal of Managed Care6d
Breakthrough Drugs Set to Achieve Blockbuster Status by 2030
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.